Chemical formula: C₂₉H₂₃F₆N₅O₃ Molecular mass: 603.516 g/mol PubChem compound: 72163100
Atogepant is indicated for prophylaxis of migraine. Atogepant shows affinity to several receptors of the calcitonin/CGRP-receptor family. In view of the clinically relevant free plasma concentrations of atogepant and the fact that CGRP and amylin-1 receptors are considered to be involved in the pathophysiology of migraine, inhibitory effects of atogepant at these receptors could be of clinical relevance. However, the precise mechanism of action of atogepant in the prophylaxis of migraine remains to be established.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CD07 | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| AQUIPTA Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Atogepant is an active ingredient of these brands:
Croatia (HR)Ireland (IE)Israel (IL)Lithuania (LT)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
